Dr. Roger S. McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto, shares groundbreaking insights as he discusses the profound connection between metabolism and mental well-being. In this episode, he explores how GLP-1s treat psychiatric illness and common metabolic comorbidities.The historical reliance on serotonin, norepinephrine, and dopamine models has proven incomplete, and many individuals with psychiatric illness continue to struggle with inadequate care. New science suggests a deeper connection between metabolism and brain health which challenges long-held beliefs about disease causes. Emerging research highlights how metabolic disruptions contribute to mental health conditions, and that GLP-1 drugs offer a path forward as they could treat mental health conditions and common metabolic problems. In essence, they have the potential to bring about profound improvements in mental health and overall well-being.⚠️ BEYOND NEUROTRANSMITTERS [07:53]:"For seven decades, we've really been at this altar of serotonin, norepinephrine and dopamine… That paradigm has been remarkably durable… but it's not been fully explanatory. Most people do not benefit adequately from current treatments."Explaining why traditional models are incomplete, Dr. McIntyre shows how new science offers hope.💊 COMBAT MEDICATION SIDE EFFECTS [45:34]:"Clinicians would be certainly on a reasonable evidentiary base of practice if they were prescribing a GLP-1 to target, for example, clozapine-induced weight gain or clozapine-induced diabetes, that would be reasonable."Dr. McIntyre offers a proven strategy for mitigating adverse effects of psychiatric medications.🚀 TRANSFORMING LIFESPANS [01:04:30]:"GLP-1s… have the potential to transform the health span and the lifespan of people living with mental illnesses by targeting on-label considerations today and potentially targeting the underlying pathophysiology of the brain-based disorder tomorrow. So stay tuned."Revealing the future of mental health, Dr. McIntyre presents a vision that offers new hope for long-term well-being.CHAPTERS:00:00 - Why GLP-1 Drugs Are Transforming Mental Health Research03:08 - The Career Shift That Linked Metabolism and Mood Disorders06:45 - Moving Beyond Serotonin to Metabolism13:18 - How GLP-1 Drugs Influence Brain Function and Neuroplasticity23:40 - Can GLP-1 Medications Reach the Brain? What the Evidence Shows32:00 - The Four Key Brain-Protective Effects of GLP-1 Therapies34:54 - How GLP-1 Reduces Cravings, Addiction, and Food Noise42:18 - When Clinicians Should Prescribe GLP-1s in Psychiatry Today53:10 - Safety Risks and Drug Interactions Psychiatrists Must Consider01:00:57 - The Future of Treatments in Psychiatry01:04:27 - Summing Up GLP-1s and Mental HealthLinks:Full transcript and show notes: https://www.psychiatrist.com/jcp/ep13-emerging-role-glp-1s-psychiatry-roger-s-mcintyre/Journal of Clinical Psychiatry: psychiatrist.com/jcp/Dr. Roger S. McIntyre: https://www.linkedin.com/in/roger-mcintyre-976bb167/#GLP1Drugs #AddictionTreatment #DepressionTreatment #MentalIllnessPrevention

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related